San Raffaele Hospital and Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.
Foundation Medicine Inc., Cambridge, MA, USA; Upstate Medical University, Syracuse, NY, USA.
Eur Urol Oncol. 2021 Oct;4(5):802-810. doi: 10.1016/j.euo.2020.10.011. Epub 2020 Nov 14.
Data on the impact of human papillomavirus (HPV) infection status and outcomes for perioperative treatments for patients with lymph node-involved penile squamous-cell carcinoma (PSCC) are lacking.
To analyze the benefit from perioperative radiotherapy (RT) for PSCC according to HPV infection status.
DESIGN, SETTING, AND PARTICIPANTS: In an international multicenter database of 1254 patients with PSCC who received inguinal lymph node dissection (ILND), 507 had suitable clinical information.
ILND, with or without chemotherapy or RT for involved lymph nodes.
Kaplan-Meier and restricted mean survival time (RMST) analyses for overall survival (OS) were performed for all patients and after propensity score-matching (PSM; n = 136), for which patient age, histology, type of penile surgical procedure, pathological tumor and nodal stage, ILND laterality, pelvic LND, and perioperative treatment were taken into account when assessing differences between HPV and HPV- patients. Finally, we looked at genomic alterations in PSCC using data from the Foundation Medicine database (n = 199) to characterize HPV PSCC.
Patients with HPV PSCC (n = 86; 17%) had lower clinical N stage (p < 0.001) and inguinal lymph node metastasis density (p < 0.001). Perioperative RT was delivered in 49 patients (9.7%), with the vast majority receiving adjuvant RT (n = 40). HPV patients had similar median OS (p = 0.1) but longer RMST than HPV- patients at different time points. Nevertheless, HPV patients treated with perioperative RT exhibited longer median OS (p = 0.015) and longer RMST compared to HPV- patients. In the PSM cohorts, HPV status remained significantly associated with longer OS after RT. The HPV- PSCC group had a higher frequency of TP53 mutations compared to HPV PSCC (75% vs 15%; p < 0.001). The results are limited by the retrospective nature of the data.
Perioperative RT was more effective in the HPV PSCC subgroup. Reasons for the enhanced radiosensitivity may be related to the lack of TP53 mutations.
We analyzed data from a large multicenter database for patients with penile cancer who had received inguinal lymph node dissection, with or without chemotherapy or radiotherapy. We found that for tumors positive for human papillomavirus (HPV), use of radiotherapy resulted in prolonged survival compared to HPV-negative tumors. On the basis of these results we are inspired to design studies on the use of radiotherapy in HPV-selected patients.
关于 HPV 感染状况对伴有淋巴结受累的阴茎鳞癌(PSCC)患者围手术期治疗结局的影响的数据尚缺乏。
分析 HPV 感染状况对 PSCC 患者接受围手术期放疗(RT)获益的影响。
设计、地点和参与者:在一项针对 1254 例接受腹股沟淋巴结清扫术(ILND)的 PSCC 患者的国际多中心数据库中,507 例患者具有合适的临床信息。
ILND,伴或不伴化疗或 RT 治疗受累淋巴结。
对所有患者和经倾向评分匹配(PSM;n = 136)后的患者进行总生存(OS)的 Kaplan-Meier 和限制性平均生存时间(RMST)分析,在评估 HPV 和 HPV-患者之间的差异时,考虑了患者年龄、组织学类型、阴茎手术类型、病理肿瘤和淋巴结分期、ILND 侧别、盆腔淋巴结清扫术和围手术期治疗。最后,我们使用来自 Foundation Medicine 数据库的数据(n = 199)来分析 PSCC 的基因组改变,以表征 HPV PSCC。
HPV PSCC 患者(n = 86;17%)具有更低的临床 N 分期(p < 0.001)和腹股沟淋巴结转移密度(p < 0.001)。49 例(9.7%)患者接受了围手术期 RT,其中绝大多数接受了辅助 RT(n = 40)。HPV 患者的中位 OS 相似(p = 0.1),但在不同时间点的 RMST 长于 HPV-患者。然而,接受围手术期 RT 的 HPV 患者的中位 OS (p = 0.015)和 RMST 长于 HPV-患者。在 PSM 队列中,HPV 状态在 RT 后仍与更长的 OS 显著相关。HPV-PSCC 组 TP53 突变的频率高于 HPV PSCC(75% vs 15%;p < 0.001)。结果受到数据回顾性的限制。
在 HPV PSCC 亚组中,围手术期 RT 更有效。放射敏感性增强的原因可能与缺乏 TP53 突变有关。
我们分析了一项针对接受腹股沟淋巴结清扫术、伴或不伴化疗或放疗的阴茎癌患者的大型多中心数据库的数据。我们发现,对于 HPV 阳性肿瘤,与 HPV 阴性肿瘤相比,放疗可延长生存时间。基于这些结果,我们受到启发,设计了针对 HPV 选择的患者使用放疗的研究。